NMDA receptor subunits: function and pharmacology

Current Opinion in Pharmacology

Volumn 7, Issue 1, 2007, Pages 39-47

  Paoletti, Pierre ^a   Neyton, Jacques ^a  

^a ECOLE NORMALE SUPÉRIEURE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 4 [2 (4 AZIDOPHENYL)ACETYLAMINO] 5,7 DICHLORO 1,2,3,4 TETRAHYDROQUINOLINE 2 CARBOXYLIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 5,7 DICHLOROKYNURENIC ACID; 7 CHLOROKYNURENIC ACID; [1 (4 BROMOPHENYL)ETHYLAMINO (2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YL)METHYL]PHOSPHONIC ACID; ARGIOTOXIN 636; BINDING PROTEIN; CGP 61594; DIZOCILPINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IFENPRODIL; ION CHANNEL; IONOTROPIC RECEPTOR; IONOTROPIC RECEPTOR ANTAGONIST; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 3A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NVP AAM 077; PHENCYCLIDINE; SPERMINE DERIVATIVE; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; BINDING SITE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; MEMORY DISORDER; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSYCHOSIS; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; WHITE MATTER;

ANIMALS; HUMANS; LIGANDS; MYELIN SHEATH; PROTEIN STRUCTURE, TERTIARY; PROTEIN SUBUNITS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 33846920665     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.08.011     Document Type: Review

References (61)

1. Dingledine R., Borges K., Bowie D., and Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev 51 (1999) 7-61
2. Cull-Candy S.G., and Leszkiewicz D.N. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE 2004 (2004) re16
3. Yamakura T., and Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 59 (1999) 279-298
4. Sasaki Y.F., Rothe T., Premkumar L.S., Das S., Cui J., Talantova M.V., Wong H.K., Gong X., Chan S.F., Zhang D., et al. Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons. J Neurophysiol 87 (2002) 2052-2063
5. Mayer M.L. Glutamate receptors at atomic resolution. Nature 440 (2006) 456-462. In this up-to-date review, the author dissects the modular organization of iGluRs and, based on recent crystallographic and functional data, gives an integrated view of their molecular operation mechanism.
6. Masuko T., Kashiwagi K., Kuno T., Nguyen N.D., Pahk A.J., Fukuchi J., Igarashi K., and Williams K. A regulatory domain (R1-R2) in the amino terminus of the N-methyl-d-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. Mol Pharmacol 55 (1999) 957-969
7. Paoletti P., Perin-Dureau F., Fayyazuddin A., Le Goff A., Callebaut I., and Neyton J. Molecular organization of a zinc binding N-terminal modulatory domain in a NMDA receptor subunit. Neuron 28 (2000) 911-925
8. Meddows E., Le Bourdelles B., Grimwood S., Wafford K., Sandhu S., Whiting P., and McIlhinney R.A. Identification of molecular determinants that are important in the assembly of N-methyl-d-aspartate receptors. J Biol Chem 276 (2001) 18795-18803
9. Furukawa H., Singh S.K., Mancusso R., and Gouaux E. Subunit arrangement and function in NMDA receptors. Nature 438 (2005) 185-192. This paper presents structural and functional evidence for heteromeric dimerization between NR1 and NR2A NMDAR subunits. As a bonus, the paper shows and discusses the structure of the glutamate-bound NR2A agonist binding site.
10. Yao Y., and Mayer M.L. Characterization of a soluble ligand binding domain of the NMDA receptor regulatory subunit NR3A. J Neurosci 26 (2006) 4559-4566. This paper presents biochemical evidence showing that the ABDs of the NR3A and NR1 subunits have a distinct pharmacological profile, despite the fact that both bind glycine.
11. Wollmuth L.P., and Sobolevsky A.I. Structure and gating of the glutamate receptor ion channel. Trends Neurosci 27 (2004) 321-328
12. Matsuda K., Kamiya Y., Matsuda S., and Yuzaki M. Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Brain Res Mol Brain Res 100 (2002) 43-52
13. Armstrong N., Sun Y., Chen G.Q., and Gouaux E. Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature 395 (1998) 913-917
14. Furukawa H., and Gouaux E. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J 22 (2003) 2873-2885
15. Inanobe A., Furukawa H., and Gouaux E. Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. Neuron 47 (2005) 71-84
16. Sun Y., Olson R., Horning M., Armstrong N., Mayer M., and Gouaux E. Mechanism of glutamate receptor desensitization. Nature 417 (2002) 245-253
17. Schorge S., and Colquhoun D. Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J Neurosci 23 (2003) 1151-1158
18. Williams K. Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44 (1993) 851-859
19. Paoletti P., Ascher P., and Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 17 (1997) 5711-5725
20. Traynelis S.F., Burgess M.F., Zheng F., Lyuboslavsky P., and Powers J.L. Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci 18 (1998) 6163-6175
21. Kew J.N., and Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179 (2005) 4-29
22. Kinarsky L., Feng B., Skifter D.A., Morley R.M., Sherman S., Jane D.E., and Monaghan D.T. Identification of subunit- and antagonist-specific amino acid residues in the N-methyl-d-aspartate receptor glutamate-binding pocket. J Pharmacol Exp Ther 313 (2005) 1066-1074
23. Feng B., Morley R.M., Jane D.E., and Monaghan D.T. The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology 48 (2005) 354-359
24. Liu L., Wong T.P., Pozza M.F., Lingenhoehl K., Wang Y., Sheng M., Auberson Y.P., and Wang Y.T. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304 (2004) 1021-1024
25. Neyton J., and Paoletti P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci 26 (2006) 1331-1333
26. Feng B., Tse H.W., Skifter D.A., Morley R., Jane D.E., and Monaghan D.T. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141 (2004) 508-516
27. Mayer M.L., Ghosal A., Dolman N.P., and Jane D.E. Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J Neurosci 26 (2006) 2852-2861
28. Raditsch M., Ruppersberg J.P., Kuner T., Gunther W., Schoepfer R., Seeburg P.H., Jahn W., and Witzemann V. Subunit-specific block of cloned NMDA receptors by argiotoxin636. FEBS Lett 324 (1993) 63-66
29. Chao J., Seiler N., Renault J., Kashiwagi K., Masuko T., Igarashi K., and Williams K. N1-dansyl-spermine and N1-(n-octanesulfonyl)-spermine, novel glutamate receptor antagonists: block and permeation of N-methyl-d-aspartate receptors. Mol Pharmacol 51 (1997) 861-871
30. Kashiwagi K., Masuko T., Nguyen C.D., Kuno T., Tanaka I., Igarashi K., and Williams K. Channel blockers acting at N-methyl-d-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. Mol Pharmacol 61 (2002) 533-545
31. Chenard B.L., and Menniti F.S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des 5 (1999) 381-404
32. Perin-Dureau F., Rachline J., Neyton J., and Paoletti P. Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci 22 (2002) 5955-5965
33. Malherbe P., Mutel V., Broger C., Perin-Dureau F., Kemp J.A., Neyton J., Paoletti P., and Kew J.N. Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. J Pharmacol Exp Ther 307 (2003) 897-905
34. Choi Y.B., and Lipton S.A. Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor. Neuron 23 (1999) 171-180
35. Rachline J., Perin-Dureau F., Le Goff A., Neyton J., and Paoletti P. The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci 25 (2005) 308-317
36. Frederickson C.J., Suh S.W., Silva D., and Thompson R.B. Importance of zinc in the central nervous system: the zinc-containing neuron. J Nutr 130 (2000) 1471S-1483S
37. Mott D.D., Doherty J.J., Zhang S., Washburn M.S., Fendley M.J., Lyuboslavsky P., Traynelis S.F., and Dingledine R. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1 (1998) 659-667
38. Jin R., Clark S., Weeks A.M., Dudman J.T., Gouaux E., and Partin K.M. Mechanism of positive allosteric modulators acting on AMPA receptors. J Neurosci 25 (2005) 9027-9036
39. Balannik V., Menniti F.S., Paternain A.V., Lerma J., and Stern-Bach Y. Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron 48 (2005) 279-288
40. 2+ and ifenprodil.
41. Kemp J.A., and McKernan R.M. NMDA receptor pathways as drug targets. Nat Neurosci 5 Suppl (2002) 1039-1042
42. Chizh B.A., and Headley P.M. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Pharm Des 11 (2005) 2977-2994
43. Kew J.N., Trube G., and Kemp J.A. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol 497 (1996) 761-772
44. Claiborne C.F., McCauley J.A., Libby B.E., Curtis N.R., Diggle H.J., Kulagowski J.J., Michelson S.R., Anderson K.D., Claremon D.A., Freidinger R.M., et al. Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett 13 (2003) 697-700
45. Layton M.E., Kelly III M.J., and Rodzinak K.J. Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Curr Top Med Chem 6 (2006) 697-709
46. •]) which show that NMDARs are expressed in the myelinating processes of oligodendrocytes and are activated under ischemic conditions. Myelin NMDARs have an unusual subunit composition with high levels of NR2C and NR3A subunits. These studies strongly suggest that oligodendrocyte NMDARs, in particular those containing NR3A, are promising therapeutic targets for preventing white matter damage.
47. •].
48. •].
49. 2+ sensitivity, indicating that this might be a distinctive property of glial NMDARs.
50. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42 (2002) 165-179
51. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
52. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.M., Mutel V., Borroni E., Kemp J.A., Bluethmann H., and Kew J.N. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22 (2002) 6713-6723
53. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40 (2003) 881-884
54. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., Bakshi K., Kamins J., Borgmann-Winter K.E., Siegel S.J., et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12 (2006) 824-828
55. Lechner S.M. Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr Opin Pharmacol 6 (2006) 75-81
56. Hess S.D., Daggett L.P., Deal C., Lu C.C., Johnson E.C., and Velicelebi G. Functional characterization of human N-methyl-d-aspartate subtype 1A/2D receptors. J Neurochem 70 (1998) 1269-1279
57. Honer M., Benke D., Laube B., Kuhse J., Heckendorn R., Allgeier H., Angst C., Monyer H., Seeburg P.H., Betz H., et al. Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors. J Biol Chem 273 (1998) 11158-11163
58. Kuner T., and Schoepfer R. Multiple structural elements determine subunit specificity of Mg2+ block in NMDA receptor channels. J Neurosci 16 (1996) 3549-3558
59. Yamakura T., Mori H., Masaki H., Shimoji K., and Mishina M. Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport 4 (1993) 687-690
60. Bresink I., Benke T.A., Collett V.J., Seal A.J., Parsons C.G., Henley J.M., and Collingridge G.L. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol 119 (1996) 195-204
61. Fischer G., Mutel V., Trube G., Malherbe P., Kew J.N., Mohacsi E., Heitz M.P., and Kemp J.A. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283 (1997) 1285-1292